CT-P13
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Diseases
Conditions
Inflammatory Bowel Diseases
Trial Timeline
Jul 10, 2024 → Jan 1, 2025
NCT ID
NCT06274294About CT-P13
CT-P13 is a phase 3 stage product being developed by Celltrion for Inflammatory Bowel Diseases. The current trial status is unknown. This product is registered under clinical trial identifier NCT06274294. Target conditions include Inflammatory Bowel Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06274294 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Inflammatory Bowel Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 85 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 23 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 77 |
| fidaxomicin | Astellas Pharma | Approved | 85 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 52 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 33 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 52 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 33 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 52 |
| MORF-057 | Eli Lilly | Phase 2 | 52 |
| LY3009104 | Eli Lilly | Phase 1 | 33 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Risankizumab | AbbVie | Approved | 85 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 33 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 33 |
| Human Papillomavirus Vaccine | Merck | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Gardasil vaccine | Merck | Pre-clinical | 23 |
| Bezlotoxumab | Merck | Approved | 85 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85